We proposed that CD4+ effector T cells are efficiently activated in tumour tissues by antigen-presenting immune cells that constitutively express MHC-II, whereas CD8+ T cells require MHC-I-restricted antigen presentation by tumour cells. The gene discussed is CD8A; the disease is neoplasm.